Education
About Us
Working with TipRanks
Follow Us
Profound Medical (TSE:PRN)
TSX:PRN
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.52Last Year’s EPS
-0.28Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 4.06%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a largely positive outlook for ProFound Medical, with significant revenue growth, improved gross margins, and successful clinical trial results. The introduction of new technology and strong market interest further bolstered the positive sentiment, although increased operating expenses and a widened net loss were noted challenges. Overall, the highlights significantly outweigh the lowlights.Company Guidance
During the Profound Medical First Quarter 2025 Financial Results Conference Call, the company provided several key metrics and updates. For the first quarter ending March 31, 2025, the company reported revenue of $2.6 million, a significant increase of 82% from $1.4 million in the same period of 2024, with $1.8 million from recurring revenue and $820,000 from one-time sales of capital equipment. The gross margin for Q1 2025 was 71%, up from 60% in Q1 2024. Operating expenses reached $13 million, compared to $8.7 million in the previous year, resulting in a net loss of $10.7 million or $0.36 per share, compared to a net loss of $6.6 million or $0.27 per share in Q1 2024. The company ended the quarter with $46.4 million in cash. Additionally, the company highlighted the promising results from the CAPTAIN clinical trial and announced the upcoming launch of the TULSA AI volume reduction module for BPH, expected to enhance procedural efficiency and expand the market.Significant Revenue Growth
First quarter 2025 revenue increased 82% to $2.6 million from $1.4 million in the same period in 2024.
Improved Gross Margin
Gross margin in Q1 2025 was 71%, an increase from 60% in Q1 2024.
Successful CAPTAIN Trial
The CAPTAIN clinical trial showed statistically significant superiority of TULSA against robotic prostatectomy, highlighting no blood loss and no overnight stays for patients.
Introduction of TULSA AI Volume Reduction Module
This new module is expected to reduce procedure time and increase the total addressable market for prostate treatments.
Strong Pipeline and Market Interest
Positive feedback from the AUA conference with significant interest in TULSA+ program and further expansion into ambulatory surgical centers and office-based laboratories.
TSE:PRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:PRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | C$6.90 | C$6.42 | -6.96% |
Mar 06, 2025 | C$10.34 | C$9.91 | -4.16% |
Nov 07, 2024 | C$12.35 | C$11.98 | -3.00% |
Aug 08, 2024 | C$12.89 | C$13.05 | +1.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Profound Medical (TSE:PRN) report earnings?
Profound Medical (TSE:PRN) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Profound Medical (TSE:PRN) earnings time?
Profound Medical (TSE:PRN) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:PRN EPS forecast?
TSE:PRN EPS forecast for the fiscal quarter 2025 (Q2) is -0.52.